1. Generics Bulletin
  2. >>Products
  3. >>Generics

Data Integrity: US FDA Guidance Seeks To Head Off Bioavailability/Bioequivalence Study Problems

 
• By Sue Sutter

Ultimate responsibility for data integrity rests with applicant, even if study is contracted out; testing site management should build a culture of quality, says the guidance, which aims to address the high-profile data integrity problems that have plagued the generic drug industry.

Drawing bullseye
A new guidance takes aim at the data integrity problems that have plagued industry in recent years • Source: Shutterstock

A new US Food and Drug Administration guidance takes aim at heading off a high-profile problem that has troubled the generic drug industry in recent years – fraud and other data integrity issues with bioavailability and bioequivalence studies.

Recommendations in the draft guidance, “Data Integrity for In Vivo Bioavailability and Bioequivalence Studies,” are aimed at addressing the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

Stada Changes Hands As CapVest Takes Control

 
• By Dave Wallace

Stada is set for new ownership after CapVest agreed to buy a controlling stake from Bain Capital and Cinven. CapVest is pledging to “deploy significant new capital” to advance Stada’s interests, with the German giant’s CEO hinting at “ambitious plans” for the future.

Sandoz Delivers On German Rivaroxaban Launch

 
• By Dave Wallace

Shortly after a German legal victory that invalidated a key Xarelto patent, Sandoz is rolling out its generic version of rivaroxaban in multiple strengths.

Teva Claims A First With US Launch Of Liraglutide For Weight Loss

 
• By Dave Wallace

Teva has announced the approval and launch of the first generic GLP-1 indicated for weight loss in the US, with the introduction of its liraglutide rival to Saxenda.

Biosimilars Help Stada Build First-Half Growth Momentum

 
• By Dave Wallace

With Stada’s growth ramping up in 2025, the German giant pointed to biosimilars – in particular its Alvotech-partnered Uzpruvo rival to Stelara – as helping to drive its financial success in the first half. Meanwhile, CEO Peter Goldschmidt also provided the latest update on a potential IPO.

More from Products

Sandoz Delivers On German Rivaroxaban Launch

 
• By Dave Wallace

Shortly after a German legal victory that invalidated a key Xarelto patent, Sandoz is rolling out its generic version of rivaroxaban in multiple strengths.

Teva Claims A First With US Launch Of Liraglutide For Weight Loss

 
• By Dave Wallace

Teva has announced the approval and launch of the first generic GLP-1 indicated for weight loss in the US, with the introduction of its liraglutide rival to Saxenda.

Abbott Snatches First Prolia/Xgeva Biosimilar Approval In Thailand

 
• By Urtė Fultinavičiūtė

Thailand will welcome the first denosumab biosimilars on its market, as Abbott builds on its Asia-Pacific portfolio.